Long-Term Outcomes of Renal Transplantation in Patients with Cystinosis.

IF 0.8
Fatih Ergül, Mustafa Yıluzar, Mert Ünal, Abdullah Kısaoğlu, İsmail Demiryılmaz, Vural Taner Yılmaz, Hüseyin Koçak
{"title":"Long-Term Outcomes of Renal Transplantation in Patients with Cystinosis.","authors":"Fatih Ergül, Mustafa Yıluzar, Mert Ünal, Abdullah Kısaoğlu, İsmail Demiryılmaz, Vural Taner Yılmaz, Hüseyin Koçak","doi":"10.1016/j.transproceed.2026.06.033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to cystine accumulation and progressive multisystem involvement. Renal failure is the clinical outcome, and renal transplantation markedly improves survival. However, long-term post-transplant outcomes remain limited. This study aimed to evaluate long-term graft and patient outcomes in cystinosis patients undergoing renal transplantation.</p><p><strong>Methods and results: </strong>This single-center retrospective case series included 6 male patients with cystinosis who underwent renal transplantation during childhood. The mean age at diagnosis was 3.9 years, and the mean follow-up period after transplantation was 12.3 years. Five patients received kidneys from living donors and one from a deceased donor. All patients were treated with cysteamine. No graft loss was observed during follow-up, and renal function remained stable in all patients. One patient developed antibody-mediated rejection while on cyclosporine, whereas no rejection episodes occurred in patients receiving tacrolimus-based regimens. Extrarenal involvement was predominantly ocular, with occasional thyroid, skeletal, and cardiac manifestations. Growth retardation was evident in all patients despite treatment.</p><p><strong>Conclusion: </strong>Renal transplantation provides excellent long-term graft and patient outcomes in cystinosis. Favorable graft survival, even in the presence of HLA mismatch, suggests a potentially protective disease-related effect. Early diagnosis, timely transplantation, and continued cysteamine therapy are essential for optimal long-term outcomes.</p>","PeriodicalId":94258,"journal":{"name":"Transplantation proceedings","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.transproceed.2026.06.033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: Cystinosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, leading to cystine accumulation and progressive multisystem involvement. Renal failure is the clinical outcome, and renal transplantation markedly improves survival. However, long-term post-transplant outcomes remain limited. This study aimed to evaluate long-term graft and patient outcomes in cystinosis patients undergoing renal transplantation.

Methods and results: This single-center retrospective case series included 6 male patients with cystinosis who underwent renal transplantation during childhood. The mean age at diagnosis was 3.9 years, and the mean follow-up period after transplantation was 12.3 years. Five patients received kidneys from living donors and one from a deceased donor. All patients were treated with cysteamine. No graft loss was observed during follow-up, and renal function remained stable in all patients. One patient developed antibody-mediated rejection while on cyclosporine, whereas no rejection episodes occurred in patients receiving tacrolimus-based regimens. Extrarenal involvement was predominantly ocular, with occasional thyroid, skeletal, and cardiac manifestations. Growth retardation was evident in all patients despite treatment.

Conclusion: Renal transplantation provides excellent long-term graft and patient outcomes in cystinosis. Favorable graft survival, even in the presence of HLA mismatch, suggests a potentially protective disease-related effect. Early diagnosis, timely transplantation, and continued cysteamine therapy are essential for optimal long-term outcomes.

胱氨酸病患者肾移植的长期预后。
背景和目的:胱氨酸病是一种罕见的常染色体隐性溶酶体贮积症,由CTNS基因突变引起,导致胱氨酸积累和进行性多系统累及。肾功能衰竭是临床结果,肾移植可显著提高生存率。然而,移植后的长期结果仍然有限。本研究旨在评估接受肾移植的胱氨酸病患者的长期移植和患者预后。方法和结果:本单中心回顾性病例系列包括6例儿童期接受肾移植的男性胱氨酸病患者。确诊时的平均年龄为3.9岁,移植后的平均随访时间为12.3年。5名患者接受了活体捐赠者的肾脏移植,1名患者接受了已故捐赠者的肾脏移植。所有患者均用半胱胺治疗。随访期间未见移植物丢失,所有患者肾功能保持稳定。一名患者在使用环孢素时出现抗体介导的排斥反应,而在接受他克莫司为基础的方案的患者中没有发生排斥反应。肾外受累主要是眼部,偶有甲状腺、骨骼和心脏表现。尽管接受了治疗,但所有患者的生长迟缓都很明显。结论:肾移植治疗胱氨酸病具有良好的长期移植效果和患者预后。即使在HLA不匹配的情况下,良好的移植物存活也表明其具有潜在的保护疾病相关作用。早期诊断、及时移植和持续半胱胺治疗是获得最佳长期结果的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书